A Pilot Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants With Post-Stroke Spasticity (The STIPS Study)
Part of paid clinical trials in Elkins Park, Pennsylvania.
- Sponsor
- Alberto Esquenazi
- Study ID
- NCT07704840
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Post-Stroke Spasticity
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Administration of BMS-986368 — DRUGAdministration of BMS-986368. Specified dose on specified days
- Placebo — DRUGInterventions: Drug: Placebo
Study Details
The goal of this clinical trial is to learn if the drug BMS-986368 works to treat post stroke spasticity in adults who have had a stroke. BMS-986368 is a designed to increase natural compounds in the body that may help calm nerves that cause muscles to be tight or spasm. The study will also learn about the safety of drug BMS-986368
Key Dates
- First listed
- Jul 15, 2026
- Start date
- Jul 31, 2026
- Status verified
- Jul 2026
- Primary completion
- Jun 30, 2027
- Completion
- Aug 31, 2027
Study Design
- Enrollment
- 42 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Administration of BMS-986368Drug: BMS-986368. Specified dose on specified days
- Placebo Comparator: PlaceboDrug: Placebo Specified dose on specified days
Primary Outcome Measure
Tardieu Scale [ Time Frame: At Week 8 ]
Central Contacts
- Kareema Murray215-663-6290
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Jeffersi=on Moss Magee Rehabilitation | Elkins Park | Pennsylvania | 19027 | Alberto Esquenazi, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Elkins Park, PA
By research site